1. Beyond Statins for LDL-C Reduction: Need for Additional Emerging Targets?

2. 62-year-old Man With Unstable Angina

3. 62-year-old Man: Physical and Laboratory Examinations

4. Clinical Questions

5. 62-year-old Man: Etiology of Hypercholesterolemia

6. Familial Hypercholesterolemia

7. Other Disorders With High LDL-C

8. Approaches Targeting Lipoprotein Metabolism

9. ARIC: What Is the Optimal LDL-C?

10. GWAS SNPs: Association Between Each Polymorphism and LDL-C

11. GWAS SNPs: Association Between Each Polymorphism and Risk of CHD

12. Effect of Each Unit Long-Term Exposure to Lower LDL-C on Risk of CHD

13. HDL-Associated SNPs

15. 62-year-old Man: Treatment Options

16. Why Have Trials Failed When a Second Agent Is Added to a Statin?

17. HPS2-THRIVE: ER Niacin With Laropiprant in Patients on Simvastatin With or Without Ezetimibe

18. IMPROVE-IT: Ezetimibe/Simvastatin Combination vs Simvastatin Monotherapy

19. Lomitapide: Phase 3 Results in Homozygous FH Patients

20. Mipomersen: Phase 3 Results in Homozygous FH Patients

21. ARIC: Nonsense Mutations in PCSK9 and CV Risk Factors in 3363 Black Participants

22. ARIC: PCSK9 Loss-of-Function Mutations, LDL-C, and CHD Risk

25. SAR236553 Phase 2: Change in LDL-C at 4-Week Dosing Intervals on Atorvastatin

26. PCSK9-Directed Therapies in Development

27. RUTHERFORD: Effect of AMG 145 on Percentage Change in LDL-C From Baseline

28. CETP Inhibitors

29. Ongoing Trials to Inhibit Inflammation Associated With Lipoproteins

30. Abbreviations

31. Abbreviations (cont)